DelveInsight’s “Non-postoperative Acute Pain Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the Non-postoperative Acute Pain, historical and forecasted epidemiology as well as the Non-postoperative Acute Pain market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Non-postoperative Acute Pain Market Share @ Non-postoperative Acute Pain Market Outlook
Key Takeaways from the Non-postoperative Acute Pain Market Report
- The increase in Non-postoperative Acute Pain Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- As per DelveInsight analysis, the Non-postoperative Acute Pain Market is anticipated to witness growth at a considerable CAGR.
- The leading Non-postoperative Acute Pain Companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, Scilex Holding, Pfizer, and others.
- Promising Non-postoperative Acute Pain Therapies such as VX-548, Dihydroergotamine, AXS-07, VYEPTI, Naltrexone-acetaminophen, ELYXYB, ZAVZPRET, NURTEC ODT, and others.
Download the report to understand which factors are driving Non-postoperative Acute Pain Epidemiology trends @ Non-postoperative Acute Pain Prevalence
Non-postoperative Acute Pain Epidemiology Segmentation in the 7MM
The epidemiology section of Non-postoperative Acute Pain offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders.
In 2023, the United States had the highest number of incident cases of non-postoperative acute pain among the seven major markets (~50,000,000 cases).
In the seven major markets, moderate to severe cases contributed approximately 60% to the total recorded diagnosed cases, in 2023.
To learn more about Non-postoperative Acute Pain treatment guidelines, visit @ Non-postoperative Acute Pain Market
Non-postoperative Acute Pain Drugs Market
The Non-postoperative Acute Pain Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. The Non-postoperative Acute Pain market size in the 7MM was around USD 3,600 million in 2023.
Non-postoperative Acute Pain Treatment Market Landscape
The Non-postoperative Acute Pain treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of CGRP inhibitors (ZAVZPRET, NURTEC ODT) and COX-2 selective NSAIDs (ELYXYB) has garnered attention. NSAIDs decrease opioid consumption by ~50%, proposed as first-line for mild-to-moderate pain.
To learn more about Non-postoperative Acute Pain treatment guidelines, visit @ Non-postoperative Acute Pain Treatment Market Landscape
Non-postoperative Acute Pain Market Outlook
The report’s outlook on the Non-postoperative Acute Pain market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Non-postoperative Acute Pain therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology.
Non-postoperative Acute Pain Drugs Uptake
The drug chapter of the Non-postoperative Acute Pain report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs. Marketed drugs include ELYXYB (Scilex Holding, launched Feb 2023), ZAVZPRET (Pfizer, FDA-approved Mar 2023), NURTEC ODT (Pfizer/Biohaven).
Major Non-postoperative Acute Pain Companies
Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others.
Learn more about the FDA-approved drugs for Non-postoperative Acute Pain @ Drugs for Non-postoperative Acute Pain Treatment
Scope of the Non-postoperative Acute Pain Market Report
- Coverage- Global
- Study Period- 2020-2034
- Non-postoperative Acute Pain Companies- Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics,and others.
- Non-postoperative Acute Pain Therapies- VX-548, Dihydroergotamine, AXS-07, VYEPTI, Naltrexone-acetaminophen, ELYXYB, ZAVZPRET, NURTEC ODT, and others.
- Non-postoperative Acute Pain Market Dynamics: Non-postoperative Acute Pain Market Drivers and Barriers
- Non-postoperative Acute Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Non-postoperative Acute Pain Drugs in development @ Non-postoperative Acute Pain Clinical Trials Assessment
Table of Content
- Key Insights
- Non-postoperative Acute Pain Report Introduction
- Non-postoperative Acute Pain Market Overview at a Glance
- Executive Summary of Non-postoperative Acute Pain
- Key Events
- Non-postoperative Acute Pain Epidemiology and Market Methodology
- Non-postoperative Acute Pain Disease Background and Overview
- Non-postoperative Acute Pain Epidemiology and Patient Population
- Patient Journey
- Non-postoperative Acute Pain Marketed Therapies
- Non-postoperative Acute Pain Emerging Therapies
- Non-postoperative Acute Pain: Market Analysis
- Non-postoperative Acute Pain KOL Views
- Non-postoperative Acute Pain SWOT Analysis
- Non-postoperative Acute Pain Unmet Needs
- Non-postoperative Acute Pain Market Access
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
